FDA Designates Majority of BD’s June 30 Alaris Pump Recall as Class I
On September 1, 2020, the U.S. Food and Drug Administration (FDA) designated three of the situations involved in BD’s June 30, 2020, previously announced voluntary recall of several models of its Alaris™ system as class I recalls. Class I recall designation indicates a reasonable probability that the use of the product will cause serious adverse health consequences or death.
- Read more about FDA Designates Majority of BD’s June 30 Alaris Pump Recall as Class I
- Add new comment
Treating Mental Health May Improve Lung Cancer Survival
Patients with lung cancer who also had mental health disorders saw improved cancer-related outcomes when their mental illness was treated, according to findings from a study published in JAMA Oncology.
FDA Approves Azacitidine Tablets for Acute Myeloid Leukemia
On September 1, 2020, the U.S. Food and Drug Administration (FDA) approved azacitidine tablets for continued treatment of patients with acute myeloid leukemia who achieved first complete remission (CR) or CR with incomplete blood count recovery following intensive induction chemotherapy and who are unable to complete intensive curative therapy.
New Roles in Oncology Nurse Navigation
In the 30 years since its inception in 1990, oncology nurse navigation has continually evolved and grown in response to patient and healthcare needs.
NCI-Partnered Global Research Initiative Confronts Tough Barriers to Cancer Progress
Since its inception in 2015, Cancer Research UK’s (CRUK) Cancer Grand Challenges initiative has led an international research effort to address the toughest barriers to progress in oncology, investing more than $130 million into seven international, multidisciplinary teams—total of 73 researcher groups in nine countries.
- Read more about NCI-Partnered Global Research Initiative Confronts Tough Barriers to Cancer Progress
- Add new comment
Lynn Rapsilber
Patricia Friend
The Case of the Pancreatic Phenomenon
Ronnie, a 68-year-old patient with stage IV pancreatic ductal adenocarcinoma, recently started palliative FOLFIRINOX chemotherapy, a regimen consisting of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin, every two weeks. During his toxicity evaluation, prior to starting his second cycle, he describes a few concerning symptoms that have been ongoing for several weeks, including unintentional weight loss of 15 kg over the last two months, significant bloating after meals, and frequent flatulence with oily stools that are difficult to flush.
Address Social Determinants by Meeting Patients Where They’re At
A hallmark principle of social work is meeting clients where they’re at. This means taking time to understand where they come from, what might be influencing how they are navigating the healthcare system, and how their cancer diagnosis personally affects them.